Gepast gebruik afspraken voor AFT
type: AppropriateUseAgreement
has part: Agreement-0
has part: Agreement-1
has part: {'description': 'Procesvoorwaarden voor trainingen en opleidingseisen om deze operatietechniek uit te kunnen voeren door plastisch chirurgen, en'}
has part: {'description': 'Procesvoorwaarden voor het opzetten van het kwaliteitsregister t.b.v. verzamelen langetermijngegevens voor kosteneffectiviteit, en risicogerichte monitoring.'}

CostEstimation-AFT-Substitution-high-Intervention-ABR-Current-default
type: Observation
data set: Kostenraming voor AFT hoog aantal borstkanker patiënten scenario
has cost type: Current
has intervention: Autologe borstreconstructie (ABR)
has number of patients: 900
has timepoint: default
has total costs: 1956150

CostEstimation-AFT-Substitution-high-Intervention-AFT-BRAVA-Additional-default
type: Observation
data set: Kostenraming voor AFT hoog aantal borstkanker patiënten scenario
has cost type: Additional
has intervention: Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA
has number of patients: 900
has timepoint: default
has total costs: 11996100

CostEstimation-AFT-Substitution-high-Intervention-AFT-BRAVA-Substitution-default
type: Observation
data set: Kostenraming voor AFT hoog aantal borstkanker patiënten scenario
has cost type: Substitution
has intervention: Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA
has number of patients: 900
has timepoint: default
has total costs: 20034000

CostEstimation-AFT-Substitution-high-Intervention-IBR-Current-default
type: Observation
data set: Kostenraming voor AFT hoog aantal borstkanker patiënten scenario
has cost type: Current
has intervention: Implant-based breast reconstruction (IBR)
has number of patients: 900
has timepoint: default
has total costs: 6081750

CostEstimation-AFT-Substitution-high-Intervention-IBR-Intervention-ABR-Intervention-AFT-BRAVA-Total-default
type: Observation
data set: Kostenraming voor AFT hoog aantal borstkanker patiënten scenario
has cost type: Total
has intervention: Autologe borstreconstructie (ABR)
has intervention: Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA
has intervention: Implant-based breast reconstruction (IBR)
has number of patients: 900
has timepoint: default
has total costs: 20034000

CostEstimation-AFT-Substitution-low-Intervention-ABR-Current-default
type: Observation
data set: Kostenraming voor AFT laag aantal borstkanker patiënten scenario
has cost type: Current
has intervention: Autologe borstreconstructie (ABR)
has number of patients: 90
has timepoint: default
has total costs: 1304100

CostEstimation-AFT-Substitution-low-Intervention-AFT-BRAVA-Additional-default
type: Observation
data set: Kostenraming voor AFT laag aantal borstkanker patiënten scenario
has cost type: Additional
has intervention: Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA
has number of patients: 600
has timepoint: default
has total costs: 7997400

CostEstimation-AFT-Substitution-low-Intervention-AFT-BRAVA-Substitution-default
type: Observation
data set: Kostenraming voor AFT laag aantal borstkanker patiënten scenario
has cost type: Substitution
has intervention: Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA
has number of patients: 600
has timepoint: default
has total costs: 13356000

CostEstimation-AFT-Substitution-low-Intervention-IBR-Current-default
type: Observation
data set: Kostenraming voor AFT laag aantal borstkanker patiënten scenario
has cost type: Current
has intervention: Implant-based breast reconstruction (IBR)
has number of patients: 510
has timepoint: default
has total costs: 4054500

CostEstimation-AFT-Substitution-low-Intervention-IBR-Intervention-ABR-Intervention-AFT-BRAVA-Total-default
type: Observation
data set: Kostenraming voor AFT laag aantal borstkanker patiënten scenario
has cost type: Total
has intervention: Autologe borstreconstructie (ABR)
has intervention: Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA
has intervention: Implant-based breast reconstruction (IBR)
has number of patients: 600
has timepoint: default
has total costs: 13356000

Zorginstituut Nederland
type: FormalOrganization
has unit: Department Zorg I

PS-AFT
type: PackageStatement
label: Borstreconstructie middels autologe vettransplantatie (AFT) na uitwendige weefsel expansie met een externe expander bij vrouwen met een totale borstverwijdering na borstkanker of ter preventie wegens genetische predispositie
contributor: Angèl Link
contributor: Ingrid de Groot
contributor: Steef Redeker
contributor: Yoka Kusumanto
issued: 2023-01-01
publisher: Team Pakket en Advies
has case number: 2022006448
has guarantee document: Waarborgendocument+autologe+vettransplantatie.pdf
has IIC assessment: IICAssessment-AFT
has package type: PointOfView
has serial number: 2022006461
has status: Definitive

TrendAssumption-AFT-high-year-default
type: Observation
data set: Geschatte trend voor AFT hoog aantal borstkanker patiënten scenario
has market penetration: 1.0
has number of patients: 900
has timepoint: default

TrendAssumption-AFT-low-year-default
type: Observation
data set: Geschatte trend voor AFT laag aantal borstkanker patiënten scenario
has market penetration: 1.0
has number of patients: 600
has timepoint: default

Agreement-0
title: {'description': 'Indicatieprotocol: aansluiten bij de indicatiecriteria en exclusiecriteria van patiënten, zoals in de BREAST-studie om in aanmerking te komen voor deze behandeling en welke professionals verantwoordelijk zijn voor de selectie van patiënten;'}

Agreement-1
title: {'description': 'Uitgebreide patiënteninformatie en richtlijnen voor professionals over hoe de patiënt voor te lichten over de voor- en nadelen van deze techniek, zodat de patiënt een weloverwogen besluit kan nemen (samen beslissen).'}

Budget Impact Analyse voor AFT
type: BIA
has cost estimation: DataSet-CostEstimation-AFT
has trend assumption: DataSet-TrendAssumption-AFT

Established Medical Science and Medical Practice - AFT
type: EMSMP
adheres to EMSMP: true
has PICO: PICOT-AFT
has systematic literature review: Systematisch literatuuronderzoek voor AFT

IICAssessment-AFT
type: IICAssessment
has assessment type: InitialAssessment
has BIA: Budget Impact Analyse voor AFT
has conclusion: Positive
has conclusion text: Sacituzumab govitecan voldoet aan de stand van de wetenschap en praktijk bij de behandeling van volwassen patiënten met inoperabele of gemetastaseerde triplenegatieve borstkanker, die twee of meer eerdere systemische therapieën hebben gekregen, waaronder één lijn taxaanbevattende therapie en tenminste één voor gevorderde ziekte. Het Zorginstituut adviseert u sacituzumab govitecan op te nemen in het verzekerde pakket voor deze indicatie. Het Zorginstituut acht een korting van tenminste 55% aangewezen. Zoals het Zorginstituut u in 2022 reeds adviseerde, dient bij de onderhandelingen te worden meegenomen dat indicatie-uitbreidingen van sacituzumab govitecan te verwachten zijn.
has cost effectiveness: CostEffectiveness
  is cost effective: false
has EMSMP: Established Medical Science and Medical Practice - AFT
has indication: Vrouwen die besloten hebben tot borstreconstructie na totale borstverwijdering ter behandeling van borstkanker
has indication: Vrouwen die besloten hebben tot borstreconstructie na totale borstverwijdering ter preventie van borstkanker wegens genetische predispositie
has intervention: Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA

Autologe vettransplantatie (AFT)
type: Intervention
applied intervention: Autologous fat transplantation (AFT)
intervention classification: Surgical
intervention rationale: Verbeteren esthetisch resultaat

Uitwendige weefsel expansie met BRAVA
type: Intervention
applied intervention: Breast Tissue Expander
intervention classification: Medical Devices
intervention rationale: Weefsel expansie voor AFT

Literatuur referentielijst voor AFT
type: SystematicLiteratureReview
had member: Eindverslag gegevens Autologe Vettransplantatie (AFT) bij borstreconstructie na borstkanker; de techniek van de toekomst bij borstreconstructies.
was generated by: Systematisch literatuuronderzoek voor AFT
item list element: Eindverslag gegevens Autologe Vettransplantatie (AFT) bij borstreconstructie na borstkanker; de techniek van de toekomst bij borstreconstructies.
number of items: 1

Literatuur zoekopdracht voor RCTs voor AFT in Cochrane op 2022-04-28
type: LiteratureSearch
ended at time: 2022-04-28T00:00:00
name: Cochrane
query: ((((autolog*) NEAR/3 (fat*)) OR lipostruct* OR lipotransfer* OR lipomodel* OR lipofill* OR ((fat*) NEAR/3 (transplant* OR graft* OR transfer* OR inject* OR infiltrate*)) OR reverseexpan*):ab,ti,kw) AND ((mammaplast* OR mammoplast* OR mastoplast* OR mastectom* OR ((breast* OR mamma*) NEAR/3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer* OR malignan*)) OR ((breast* OR mamma*) NEAR/6 (oncol*)) OR mammacarcin*):ab,ti,kw) AND ((((clinical* OR case* OR family* OR intervent* OR longitudinal* OR open OR prospect* OR retrospect* OR multicent*) NEAR/2 (study OR studies OR article* OR trial* OR evaluation*)) OR case-report* OR case-serie* OR ((communit*) NEAR/2 (trial*)) OR RCT OR RCTS OR randomi* OR placebo* OR ((single* or double* or triple* or treble*) AND (blind* or mask*)) OR ((phase*) NEAR/3 (1 OR one OR I OR 2 OR two OR II OR 3 OR three OR III OR 4 OR four OR IV) NEAR/6 (trial* OR stud*))):ab,ti,kw).
target: www.cochranelibrary.com
has evidence type: OBI_0003699

Literatuur zoekopdracht voor Systematic Reviews on AFT in Cochrane op 2022-04-28
type: LiteratureSearch
ended at time: 2022-04-28T00:00:00
name: Cochrane
query: ((((autolog*) NEAR/3 (fat*)) OR lipostruct* OR lipotransfer* OR lipomodel* OR lipofill* OR ((fat*) NEAR/3 (transplant* OR graft* OR transfer* OR inject* OR infiltrate*)) OR reverseexpan*):ab,ti,kw) AND ((mammaplast* OR mammoplast* OR mastoplast* OR mastectom* OR ((breast* OR mamma*) NEAR/3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer* OR malignan*)) OR ((breast* OR mamma*) NEAR/6 (oncol*)) OR mammacarcin*):ab,ti,kw) AND ((systematic-review*):ab,ti,kw)
target: www.cochranelibrary.com
has evidence type: SystematicLiteratureReview

Literatuur zoekopdracht voor RCTs voor AFT in Embase op 2022-04-28
type: LiteratureSearch
ended at time: 2022-04-28T00:00:00
name: Embase
query: ('autologous fat'/de OR 'lipotransfer'/de OR 'lipomodelling'/de OR 'adipose tissue transplantation'/de OR (('adipose tissue'/exp) AND ('transplantation'/de )) OR 'autologous fat grafting'/de OR 'autologous fat transplantation'/de OR 'autologous fat transfer'/de OR 'autologous fat graft'/de OR 'autologous fat injection'/de OR (((autolog*) NEAR/3 (fat*)) OR lipostruct* OR lipotransfer* OR lipomodel* OR lipofill* OR ((fat*) NEAR/3 (transplant* OR graft* OR transfer* OR inject* OR infiltrate*)) OR reverse-expan*):ab,ti,kw) AND ('breast tumor'/exp OR 'mastectomy'/exp OR (mammaplast* OR mammoplast* OR mastoplast* OR mastectom* OR ((breast* OR mamma*) NEAR/3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer* OR malignan*)) OR ((breast* OR mamma*) NEAR/6 (oncol*)) OR mammacarcin*):ab,ti,kw) AND ('clinical study'/exp OR (((clinical* OR case* OR family* OR intervent* OR longitudinal* OR open OR prospect* OR retrospect* OR multicent*) NEAR/2 (study OR studies OR article* OR trial* OR evaluation*)) OR case-report* OR case-serie* OR ((communit*) NEAR/2 (trial*)) OR RCT OR RCTS OR randomi* OR placebo* OR ((single* or double* or triple* or treble*) AND (blind* or mask*)) OR ((phase*) NEAR/3 (1 OR one OR I OR 2 OR two OR II OR 3 OR three OR III OR 4 OR four OR IV) NEAR/6 (trial* OR stud*))):ab,ti,kw) NOT ([Conference Abstract]/lim OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'chapter'/it OR 'conference abstract'/it OR 'conference paper'/it OR 'conference review'/it OR 'editorial'/it OR 'erratum'/it OR [preprint]/lim) NOT ('systematic review'/de OR 'systematic review (topic)'/de OR (systematic-review*):ab,ti,kw)
target: www.embase.com
has evidence type: OBI_0003699

Literatuur zoekopdracht voor Systematic Reviews on AFT in Embase op 2022-04-28
type: LiteratureSearch
ended at time: 2022-04-28T00:00:00
name: Embase
query: ('autologous fat'/de OR 'lipotransfer'/de OR 'lipomodelling'/de OR 'adipose tissue transplantation'/de OR (('adipose tissue'/exp) AND ('transplantation'/de )) OR 'autologous fat grafting'/de OR 'autologous fat transplantation'/de OR 'autologous fat transfer'/de OR 'autologous fat graft'/de OR 'autologous fat injection'/de OR (((autolog*) NEAR/3 (fat*)) OR lipostruct* OR lipotransfer* OR lipomodel* OR lipofill* OR ((fat*) NEAR/3 (transplant* OR graft* OR transfer* OR inject* OR infiltrate*)) OR reverse-expan*):ab,ti,kw) AND ('breast tumor'/exp OR 'mastectomy'/exp OR (mammaplast* OR mammoplast* OR mastoplast* OR mastectom* OR ((breast* OR mamma*) NEAR/3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer* OR malignan*)) OR ((breast* OR mamma*) NEAR/6 (oncol*)) OR mammacarcin*):ab,ti,kw) AND ('systematic review'/de OR 'systematic review (topic)'/de OR (systematic-review*):ab,ti,kw)
target: www.embase.com
has evidence type: SystematicLiteratureReview

Literatuur zoekopdracht voor RCTs voor AFT in Medline op 2022-04-28
type: LiteratureSearch
ended at time: 2022-04-28T00:00:00
name: Medline
query: (((exp "Adipose Tissue"/) AND ("Transplantation"/ OR "Transplantation, Autologous"/ OR "Tissue Transplantation"/ OR tr.fs)) OR (((autolog*) ADJ3 (fat*)) OR lipostruct* OR lipotransfer* OR lipomodel* OR lipofill* OR ((fat*) ADJ3 (transplant* OR graft* OR transfer* OR inject* OR infiltrate*)) OR reverse-expan*).ab,ti,kf.) AND (exp "Breast Neoplasms"/ OR exp "Mastectomy"/ OR (mammaplast* OR mammoplast* OR mastoplast* OR mastectom* OR ((breast* OR mamma*) ADJ3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer* OR malignan*)) OR ((breast* OR mamma*) ADJ6 (oncol*)) OR mammacarcin*).ab,ti,kf.) AND ("Clinical Study".pt OR "Clinical Trial".pt OR "Adaptive Clinical Trial".pt OR "Clinical Trial, Phase I".pt OR "Clinical Trial, Phase II".pt OR "Clinical Trial, Phase III".pt OR "Clinical Trial, Phase IV".pt OR "Controlled Clinical Trial".pt OR "Randomized Controlled Trial".pt OR "Equivalence Trial".pt OR "Pragmatic Clinical Trial".pt OR "Clinical Trial Protocol".pt OR "Observational Study".pt OR exp "Clinical Studies as Topic"/ OR (((clinical* OR case* OR family* OR intervent* OR longitudinal* OR open OR prospect* OR retrospect* OR multicent*) ADJ2 (study OR studies OR article* OR trial* OR evaluation*)) OR case-report* OR case-serie* OR ((communit*) ADJ2 (trial*)) OR RCT OR RCTS OR randomi* OR placebo* OR ((single* or double* or triple* or treble*) AND (blind* or mask*)) OR ((phase*) ADJ3 (1 OR one OR I OR 2 OR two OR II OR 3 OR three OR III OR 4 OR four OR IV) ADJ6 (trial* OR stud*))).ab,ti,kf.) NOT ("Editorial".pt. OR "Comment".pt. OR "Letter".pt. OR "News".pt. OR "Congress".pt. OR "Meeting Abstract".pt. OR "Abstracts".pt. OR "Academic Dissertation".pt. OR "Published Erratum".pt. OR (book* OR chapter* OR dissertation abstract*).pt.) NOT ("Systematic Reviews as Topic"/ OR "Systematic Review".pt. OR (systematic-review*).ab,ti,kf.)
target: www.medline.com
has evidence type: OBI_0003699

Literatuur zoekopdracht voor Systematic Reviews on AFT in Medline op 2022-04-28
type: LiteratureSearch
ended at time: 2022-04-28T00:00:00
name: Medline
query: (((exp "Adipose Tissue"/) AND ("Transplantation"/ OR "Transplantation, Autologous"/ OR "Tissue Transplantation"/ OR tr.fs)) OR (((autolog*) ADJ3 (fat*)) OR lipostruct* OR lipotransfer* OR lipomodel* OR lipofill* OR ((fat*) ADJ3 (transplant* OR graft* OR transfer* OR inject* OR infiltrate*)) OR reverse-expan*).ab,ti,kf.) AND (exp "Breast Neoplasms"/ OR exp "Mastectomy"/ OR (mammaplast* OR mammoplast* OR mastoplast* OR mastectom* OR ((breast* OR mamma*) ADJ3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer* OR malignan*)) OR ((breast* OR mamma*) ADJ6 (oncol*)) OR mammacarcin*).ab,ti,kf.) AND ("Systematic Reviews as Topic"/ OR "Systematic Review".pt. OR (systematicreview*).ab,ti,kf.)
target: www.medline.com
has evidence type: SystematicLiteratureReview

Department Zorg I
type: OrganizationalUnit
has unit: Team Pakket en Advies

Patient satisfaction with breast
type: Outcome
outcome classification: Patient-reported
outcome measurement: BREAST-Q - satisfaction with breast
is surrogate outcome: false

BREAST-Q - physical wellbeing
type: Outcome
outcome classification: Patient-reported
outcome measurement: BREAST-Q - physical wellbeing
is surrogate outcome: false

BREAST-Q - psychosocial wellbeing
type: Outcome
outcome classification: Patient-reported
outcome measurement: BREAST-Q - psychosocial wellbeing
is surrogate outcome: false

BREAST-Q - sexual well-being
type: Outcome
outcome classification: Patient-reported
outcome measurement: BREAST-Q - sexual well-being
is surrogate outcome: false

Breast volume retention
type: Outcome
outcome classification: Aesthetic
outcome measurement: Breast volume retention
specific metric: 3D fotografie met VECTRA®XT (ml)
is surrogate outcome: false

Non-serious side effects
type: Outcome
outcome classification: Adverse events
outcome measurement: Number of non-serious side effects
is surrogate outcome: false

Serious perioperative complications
type: Outcome
outcome classification: Adverse events
outcome measurement: Number of serious complications
is surrogate outcome: false

…
type: OutcomeGroup
endpoint: 12 to 60 months post-intervention
outcome: Locoregional oncologic events

…
type: OutcomeGroup
endpoint: 12 months post-intervention
outcome: Patient satisfaction with breast
outcome: BREAST-Q - physical wellbeing
outcome: BREAST-Q - psychosocial wellbeing
outcome: BREAST-Q - sexual well-being

…
type: OutcomeGroup
endpoint: Between 6 and 12 months post-intervention
outcome: Breast volume retention
outcome: Locoregional oncologic events

…
type: OutcomeGroup
endpoint: 12 Peri- en postoperative till 12 months postintervention
outcome: Non-serious side effects
outcome: Serious perioperative complications

OutcomeMeasurement-BREASTQPatientSatisfactionWithBreast-MD
type: STATO_0000457
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: Patient satisfaction with breast
STATO_0000129: 9.9

OutcomeMeasurement-BREASTQPhysicalWellbeing-MD
type: STATO_0000457
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: BREAST-Q - physical wellbeing
STATO_0000129: 7.6

OutcomeMeasurement-BREASTQPsychosocialWellbeing-MD
type: STATO_0000457
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: BREAST-Q - psychosocial wellbeing
STATO_0000129: 1.3

OutcomeMeasurement-BREASTQSexualWellbeing-MD
type: STATO_0000457
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: BREAST-Q - sexual well-being
STATO_0000129: 2.9

OutcomeMeasurement-BreastvolumeRetention-SMD
type: STATO_0000176
IAO_0000039: UO_0000098
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: Breast volume retention
STATO_0000129: -9.9

OutcomeMeasurement-LocoregionalOncologicEvents-AbsoluteDifference
type: STATO_0000614
IAO_0000039: UO_0000187
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: Locoregional oncologic events
STATO_0000129: -1.1

OutcomeMeasurement-LocoregionalOncologicEvents-RR
type: STATO_0000245
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: Locoregional oncologic events
STATO_0000129: 0.85

OutcomeMeasurement-SeriousPerioperativeComplications-AbsoluteDifference
type: STATO_0000614
IAO_0000039: UO_0000187
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: Serious perioperative complications
STATO_0000129: -14.5

OutcomeMeasurement-SeriousPerioperativeComplications-RR
type: STATO_0000245
IAO_0000136: Cohort-BREAST-Comparator
IAO_0000136: Cohort-BREAST-Intervention
IAO_0000221: Serious perioperative complications
STATO_0000129: 0.18

Geschatte trend voor AFT hoog aantal borstkanker patiënten scenario
type: DataSet
has scenario: Scenario met maximum aantal AFT gebruik

Geschatte trend voor AFT laag aantal borstkanker patiënten scenario
type: DataSet
has scenario: Scenario met minimum aantal AFT-gebruik

Eindverslag gegevens Autologe Vettransplantatie (AFT) bij borstreconstructie na borstkanker; de techniek van de toekomst bij borstreconstructies.
type: Manuscript

Team Pakket en Advies
type: OrganizationalUnit

Locoregional oncologic events
type: Outcome
outcome classification: Adverse events
outcome measurement: Number of locoregional oncologic events
is surrogate outcome: false

Vrouwen die besloten hebben tot borstreconstructie na totale borstverwijdering ter behandeling van borstkanker
type: Population
condition: Breast Cancer
sex: Female
treatment: Simple mastectomy

Vrouwen die besloten hebben tot borstreconstructie na totale borstverwijdering ter preventie van borstkanker wegens genetische predispositie
type: Population
condition: Genetic predisposition to breast cancer
treatment: Simple mastectomy

Systematisch literatuuronderzoek voor AFT
type: SystematicLiteratureReview
has part: Literatuur zoekopdracht voor RCTs voor AFT in Cochrane op 2022-04-28
has part: Literatuur zoekopdracht voor Systematic Reviews on AFT in Cochrane op 2022-04-28
has part: Literatuur zoekopdracht voor RCTs voor AFT in Embase op 2022-04-28
has part: Literatuur zoekopdracht voor Systematic Reviews on AFT in Embase op 2022-04-28
has part: Literatuur zoekopdracht voor RCTs voor AFT in Medline op 2022-04-28
has part: Literatuur zoekopdracht voor Systematic Reviews on AFT in Medline op 2022-04-28
result: Literatuur referentielijst voor AFT

Scenario met maximum aantal AFT gebruik
type: Scenario
description: Scenario met maximum aantal AFT gebruik

Scenario met minimum aantal AFT-gebruik
type: Scenario
description: Scenario met minimum aantal AFT-gebruik

Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy (BREAST)
type: OBI_0003699
source: Clinicaltrials.gov

Kostenraming voor AFT hoog aantal borstkanker patiënten scenario
type: DataSet
has scenario: Scenario met maximum aantal AFT gebruik

Kostenraming voor AFT laag aantal borstkanker patiënten scenario
type: DataSet
has scenario: Scenario met minimum aantal AFT-gebruik

Autologe borstreconstructie (ABR)
type: Intervention
applied intervention: Autologous breast reconstruction (ABR)
intervention classification: Surgical
intervention rationale: Herstellen borstvolume en -vorm
has care product code: 990004018

Implant-based breast reconstruction (IBR)
type: Intervention
applied intervention: Implant-based breast reconstruction (IBR)
intervention classification: Surgical
intervention rationale: Herstellen borstvolume en -vorm
has care product code: 990004080

Autologe vettransplantatie (AFT) na uitwendige weefsel expansie met BRAVA
type: Intervention
applied intervention: Autologous fat transplantation (AFT) after external tissue expansion using BRAVA
child intervention: Autologe vettransplantatie (AFT)
child intervention: Uitwendige weefsel expansie met BRAVA
intervention classification: Surgical
intervention rationale: Herstellen borstvolume en -vorm
has care activity code: 033973
has care product code: 982017017

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 0.24
BFO_0000051: STATO_0000315
  STATO_0000129: 3.03
IAO_0000136: OutcomeMeasurement-LocoregionalOncologicEvents-RR

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 7.32
BFO_0000051: STATO_0000315
  STATO_0000129: 4.72
IAO_0000136: OutcomeMeasurement-BREASTQPsychosocialWellbeing-MD

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 0.76
BFO_0000051: STATO_0000315
  STATO_0000129: 0.04
IAO_0000136: OutcomeMeasurement-SeriousPerioperativeComplications-RR

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 9.27
BFO_0000051: STATO_0000315
  STATO_0000129: -3.47
IAO_0000136: OutcomeMeasurement-BREASTQSexualWellbeing-MD

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: -37.04
BFO_0000051: STATO_0000314
  STATO_0000129: 17.24
IAO_0000136: OutcomeMeasurement-BreastvolumeRetention-SMD

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 15.88
BFO_0000051: STATO_0000315
  STATO_0000129: 3.92
IAO_0000136: OutcomeMeasurement-BREASTQPatientSatisfactionWithBreast-MD

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: -6.2
BFO_0000051: STATO_0000314
  STATO_0000129: 149
IAO_0000136: OutcomeMeasurement-LocoregionalOncologicEvents-AbsoluteDifference

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: -42
BFO_0000051: STATO_0000315
  STATO_0000129: -169
IAO_0000136: OutcomeMeasurement-SeriousPerioperativeComplications-AbsoluteDifference

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: 2.19
BFO_0000051: STATO_0000314
  STATO_0000129: 13.01
IAO_0000136: OutcomeMeasurement-BREASTQPhysicalWellbeing-MD